RxDoctor Payments Data

Anton Galich, MD

Urology · Olathe, KSNPI 1487605226

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,292 of the $4,869 with a category attached, or 88.2%. It is spread thinly across 44 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.

$4,869in general payments, 2019–2025

Across 158 payments — averaging $30.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$787
  • Coloplast$670
  • Astellas Pharma US Inc$407
  • Medtronic$345
  • AbbVie$315
  • Histosonics, Inc.$297
  • plus $2K from 38 others

What the payments were for

  • Travel & lodging$3537%
  • Food & beverage$4,29288%
  • Education$2235%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,869 in reported general payments places this provider in the 65th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$224,991
Medicare patients
569
Services billed
3,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron120$74,957
GemtesaVibegron56$42,602
Tamsulosin Hcl520$5,676
Finasteride362$5,384
Trospium Chloride64$3,233
Potassium Citrate ErPotassium Citrate32$3,157
Oxybutynin Chloride ErOxybutynin Chloride95$1,985
Methenamine Hippurate14$1,283
Terazosin Hcl99$1,006
Estradiol16$898
Tolterodine Tartrate ErTolterodine Tartrate17$656
Solifenacin Succinate21$653
Cefadroxil99$490
Bicalutamide13$432
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen104$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$407$74,957120 claims
Sumitomo Pharma America, Inc.Gemtesa$44$42,60256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 urology providers in Kansas.

Other urology in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →